UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Sep

    10

    Gen Z and Millennial Patients Find “Rheum for Improvement” in Disease Management

    Sep

    08

    The profound impact on the lives of people living with thymidine kinase 2 deficiency (TK2d)

    Sep

    03

    The Sniff That Saves: Honoring Service Dogs This Awareness Month

    Aug

    29

    Decades of Dedication: UCB’s Ongoing Commitment to Epilepsy through the Family Epilepsy Scholarship Program™

    Aug

    12

    Our Growth Helps Elevate Patient Lives

    Aug

    01

    Beyond Awareness: Uniting for a Brighter Future at the HS Summit

    Jul

    31

    Strength in Connection: The Role of Supportive Networks in Psoriatic Disease

    Jul

    30

    Building Talent, Shaping Futures: Why Interns Matter

    Jun

    27

    UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

    Jun

    20

    UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference